- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06308055
Abiomed Impella RT-DAQ - Observationsstudie
Abiomed IMPELLA-RT-DAQ - Impella Real Time Data AcQuisition
Abiomed IMPELLA-RT-DAQ - Impella Real Time Data AcQuisition
Studieoversigt
Detaljeret beskrivelse
The objective of this study is to develop algorithms for determining the cardiac output through the synchronous acquisition of hemodynamic data from the pulmonary artery catheter or other pressure sensors and Impella using a network module, which can replace invasive hemodynamic monitoring in the future.
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Kirstin Starke
- Telefonnummer: +49 241 8860
- E-mail: KStarke@ITS.JNJ.com
Studiesteder
-
-
MI
-
Milan, MI, Italien, 20132
- Rekruttering
- IRCCS Ospedale San Raffaele
-
Ledende efterforsker:
- Alberto Zangrillo, MD
-
Underforsker:
- Luca Baldetti, MD
-
-
-
-
-
Basel, Schweiz
- Rekruttering
- Universitätsspital Basel
-
Kontakt:
- Patrick Hunziker, MD
-
Ledende efterforsker:
- Patrick Hunziker, MD
-
-
-
-
North Rhine-Westphalia
-
Aachen, North Rhine-Westphalia, Tyskland, 52074
- Aktiv, ikke rekrutterende
- Uniklinik RWTH Aachen
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Tyskland, 24105
- Rekruttering
- UKSH Campus Kiel
-
Ledende efterforsker:
- Bernd Panholzer, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Patients requiring cardiac Impella pump-support and intensive care therapy including cardiac output monitoring, eg. by pulmonary artery catheter at some point of therapy.
Initially, a collection of 250 patient days is aimed for. It is expected that each patient will be monitored by PAC for at least 48 hours, thus approximately 125 patients will be needed to achieve study objectives.
Beskrivelse
Inclusion Criteria:
-
Ongoing or planned intensive care management with Impella support
-
Presence or planned placement of a cardiac output measurement
- Preferentially pulmonary catheter (including cardiac output (CO) preferred as continuous measurement)
- Other means of discontinuous CO measurement incl. echocardiography, other thermodilution methods
Exclusion Criteria:
- Age < 18 years
- Pregnancy
- Anticipated support duration <24 h
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Collection of hemodynamic parameters (Cardiac Output in l/min)
Tidsramme: From Impella insertion unitl Impella support is permanently weaned, on average 2 days
|
Synchronous data acquisition of the Impella system parameters (pressure measurement, motor current, operating data) and the monitoring system (Philipps IntelliVue) using a network module (HighDim) that is connected by either a wired or wireless access. |
From Impella insertion unitl Impella support is permanently weaned, on average 2 days
|
|
Collection of hemodynamic parameters (Blood Pressure in mmHg, Pulmonary Artery Pressure in mmHg, Central Venous Pressure in mmHg, Pulmonary Capillary Wedge Pressure in mmHg)
Tidsramme: From Impella insertion unitl Impella support is permanently weaned, on average 2 days
|
Synchronous data acquisition of the Impella system parameters (pressure measurement, motor current, operating data) and the monitoring system (Philipps IntelliVue) using a network module (HighDim) that is connected by either a wired or wireless access. |
From Impella insertion unitl Impella support is permanently weaned, on average 2 days
|
|
Collection of hemodynamic parameters (Mixed Venous Saturation in %)
Tidsramme: From Impella insertion unitl Impella support is permanently weaned, on average 2 days
|
Synchronous data acquisition of the Impella system parameters (pressure measurement, motor current, operating data) and the monitoring system (Philipps IntelliVue) using a network module (HighDim) that is connected by either a wired or wireless access. |
From Impella insertion unitl Impella support is permanently weaned, on average 2 days
|
|
Collection of hemodynamic parameters (Pulmonary Vascular Resistance in In dynes/sec/cm-5 )
Tidsramme: From Impella insertion unitl Impella support is permanently weaned, on average 2 days
|
Synchronous data acquisition of the Impella system parameters (pressure measurement, motor current, operating data) and the monitoring system (Philipps IntelliVue) using a network module (HighDim) that is connected by either a wired or wireless access. |
From Impella insertion unitl Impella support is permanently weaned, on average 2 days
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Sats for patientoverlevelse
Tidsramme: Når Impella-støtten er permanent fravænnet, i gennemsnit 2 dage
|
Når Impella-støtten er permanent fravænnet, i gennemsnit 2 dage
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Alexander Kersten, MD, Uniklinik RWTH Aachen, Klinik für Kardiologie, Angiologie und Internistische Intensivmedizin
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2022-R01
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .